Mutations in more than 70 genes cause hereditary anemias (HA), a highly heterogeneous group of rare/low frequency disorders in which we included: hyporegenerative anemias, as congenital dyserythropoietic anemia (CDA) and Diamond-Blackfan anemia; hemolytic anemias due to erythrocyte membrane defects, as hereditary spherocytosis and stomatocytosis; hemolytic anemias due to enzymatic defects. The study describes the diagnostic workflow for HA, based on the development of two consecutive versions of a targeted-NGS panel, including 34 and 71 genes, respectively. Seventy-four probands from 62 unrelated families were investigated. Our study includes the most comprehensive gene set for these anemias and the largest cohort of patients described so far. We obtained an overall diagnostic yield of 64.9%. Despite 54.2% of cases showed conclusive diagnosis fitting well to the clinical suspicion, the multi-gene analysis modified the original clinical diagnosis in 45.8% of patients (nonmatched phenotype-genotype). Of note, 81.8% of nonmatched patients were clinically suspected to suffer from CDA. Particularly, 45.5% of the probands originally classified as CDA exhibited a conclusive diagnosis of chronic anemia due to enzymatic defects, mainly due to mutations in PKLR gene. Interestingly, we also identified a syndromic CDA patient with mild anemia and epilepsy, showing a homozygous mutation in CAD gene, recently associated to early infantile epileptic encephalopathy-50 and CDA-like anemia. Finally, we described a patient showing marked iron overload due to the coinheritance of PIEZO1 and SEC23B mutations, demonstrating that the multi-gene approach is valuable not only for achieving a correct and definitive diagnosis, but also for guiding treatment.
require several lines of investigation. [1] [2] [3] [4] The first is based on clinical features (evaluation of complete blood count), positive familial history, and the observation of a peripheral blood smear. The second line comprises biochemical tests and highly specialized analyzes, as the ektacytometry for the diagnosis of erythrocytes membrane defects, which are available only in few laboratories in the world. The last line includes the molecular analysis of the causative gene by direct sequencing. Unfortunately, in several cases these investigations fail to achieve the correct diagnosis, especially when the family history is uninformative or when routine laboratory tests produce unclear data.
Due to the failure of the current diagnostic workflow to find a definitive and correct diagnosis of HA, next-generation sequencing (NGS) is making its way on this field. The major current application of NGS in diagnostics is through disease-targeted tests for which multiple causal genes are known. Some studies have already demonstrated the usefulness of targeted-NGS (t-NGS) approach in the investigation of specific subtypes of HA patients. The multi-gene panels described so far include a gene set ranging from 28 to 40 loci causative of CDA, DBA, hemolytic anemias due to enzymatic defects, HS, and sideroblastic anemia. [7] [8] [9] We herein described the diagnostic workflow that we established for molecular diagnosis of hereditary hemolytic anemias, based on the development of two consecutive versions of a t-NGS panel, comprising 34 and 71 causative/candidate genes, respectively. We showed the results obtained by the analysis of 74 probands from 62 unrelated families. This is the largest cohort of patients and the most comprehensive gene set for this subset of anemias described so far. Diagnosis was based on history, clinical findings, laboratory data, morphological analysis of peripheral blood and/or aspirated bone marrow, whenever available. [1] [2] [3] [4] For HS/HST patients, diagnosis was also based on indirect tests (osmotic fragility of erythrocyte, AGLT50, EMA binding test), as well as on ektacytometry. Local university ethical committees approved collection of patient's data from Medical Genetics Ambulatory in Naples (University Federico II, DAIMedLab).
DNA samples from the patients were obtained after signed informed consent and according to the Declaration of Helsinki. Whenever possible, affected and unaffected relatives were also enrolled to correctly assess the pathogenicity of each variant by the analysis of family segregation.
Genomic DNA (gDNA) preparation was performed as previously described. 10 To evaluate the quality of the extracted gDNA before the Figure 1B ). Particularly, two probands originally suspected of CDAII, RP0_36, and RP0_39, were conclusively diagnosed as CDAIa and CDAIb, respectively; while, RP0_59 and RP1_41, both initially suspected of CDAI, were diagnosed as CDAIV and CDA variant due to a heterozygous mutation in ALAS2, as recently described (Tables   1 and 2 ; Supporting Information Tables S3). Information Table S3 ). Both patients exhibited heterozygous missense mutations in the C-terminal intracellular domain of PIEZO1 protein that forms the pore of the channel, mediating the ion conduction and the cation selectivity. 18, 19 Of note, RP1_63 patient also coinherited a heterozygous G6PD mutation, namely the G6PD Sierra
Leone, that was categorized with enzymatic activity of class III (Tables   1 and 2 ). 20 The remaining cases, RP1_16 and RP1_17, were two siblings carrying a missense variant in homozygous state that falls in one of the last transmembrane domains of the protein (Table 2 ). Both probands exhibited similar clinical features most resembling those of DHS1 patients: mild anemia (Hb 11.7-12.8 g/dL) with macrocytosis (MCV 91 fl) and reticulocytosis (145 920-266 880/mL) (Supporting Information Table S3 ). Table S3 ), carrying two recently described pathogenic missense mutations in GPI, the causative gene of hemolytic nonspherocytic anemia due to glucose phosphate isomerase deficiency (Table 2) . 16 The second case, RP1_85, was a 29-year-old girl with severe normocytic anemia (Hb 6.6 g/dL, MCV 86.0 fl) and reticulocytosis (218 000/mL) (Supporting Information note, these patients presented clinical data and morphological features of the bone marrow mostly resembling those of both CDAI and CDAII (Table 3) . It is important to underline that almost all the patients originally classified as CDA and subsequently diagnosed as chronic hemolytic anemia due to enzyme defects were transfusion-dependent, with subsequent reduced reliability of the enzyme assays.
| Congenital hemolytic anemias misdiagnosed as CDAs
Finally, we also identified a case of syndromic CDA due the homozygous mutation p.Arg1789Gln in CAD gene, encoding a trifunctional protein involved in the pathway of pyrimidine biosynthesis ( Table 2 ).
The proband, RP1_112, was a 6.5-year-old boy with mild macrocytic anemia (Hb 11.3 g/dL, MCV 90.0 fl) and increased RDW (19.0%), suffering also from epilepsy (Supporting Information Table S3 ).
| Additive effect of multiple disease-causing genotypes
Among the patients originally diagnosed as DHS we identified a 35-year-old male, RP1_5, showing a causative PIEZO1 mutation in heterozygous state, thus confirming the clinical suspicion of DHS1. 4 Interestingly, the patient exhibited also homozygosity for the most common causative mutation of CDAII, the Glu109Lys-SEC23B (Table 2) . 1 His clinical picture was suggestive of DHS1; indeed, he presented mild anemia (Hb 13.5 g/dL) with macrocytosis (MCV 97.9 fL) and reticulocytosis (117 000/lL) (Supporting Information Table S3 ). Nevertheless, ektacytometry analysis highlighted a peculiar bell shape curve with reduced DImax and right shift of the Omin point. Interestingly, the coinheritance of PIEZO1 and SEC23B causative mutations resulted in marked iron overload, with very high ferritin levels (1938 ng/mL) and increased transferrin saturation (TSAT 88%).
| D I SCUSSION
Clinical and molecular definition of patients with HA may be very hard to obtain. For some conditions, the great phenotypic variability is partially explained either with high genetic heterogeneity or with reduced penetrance and variable expressivity. [1] [2] [3] [4] In the last decade, remarkable progresses have been made in discovering new disease genes involved in red blood disorders. This increasing genetic heterogeneity underlines the problem of a very complex differential diagnosis. 3 It is proper in this context that the multi-gene panel testing takes place. Some t-NGS panels for the diagnosis of HA have been already described. These studies analyzed a cohort of patients ranging from 19 to 57 cases by means of custom panels comprising a smaller gene set of 28-40 loci causative of some RBC membrane defects, CDA, DBA, hemolytic anemias due to enzymatic defects, sideroblastic anemia. [7] [8] [9] We herein described the largest cohort of patients and the most comprehensive gene set for this subset of anemias described so far.
Clinical diagnosis of hereditary hemolytic anemias is often inaccurate due to overlapping phenotypes. Of note, our multi-gene panel analysis modified the original clinical diagnosis in 45.8% of patients.
Our data demonstrated that CDAs are the most difficult to diagnose at clinical level. This is not surprising if we consider that dyserythropoiesis appears to be a common morphologic feature in several conditions. Clinical features of CDA patients conclusively diagnosed as PK deficiency and HS, and between CDAI and DHS. 1, 3 Of note, a subtype of HST with overlapping features of CDA was already associated to a specific de novo mutation, p.Gly796Arg, in SLC4A1 gene, encoding band 3. 3 In our cohort of patients we identified a second case, RP1_68, carrying the same mutation, although with a different nucleotide replacement (Table 2) .
Contrary to CDAs, most of the patients (84.6%) originally classified as erythrocyte membrane defects showed conclusive diagnosis fitting well to the clinical suspicion. This could be explained by the availability of well-defined lines of investigations, as well as of reliable laboratory assays. 3, 4 Finally, the multigenic approach also allowed us identifying patients showing multiple disease-associated variants, suggesting complex inheritance. This was the case of a DHS1 patient that resulted also affected by CDAII. Interestingly, the coinheritance of PIEZO1 and SEC23B causative genotypes accounted for marked iron overload in this patient. Indeed, both DHS1 and CDAII presented iron loading anemia even in absence of transfusion regimen, although with different pathomechanisms. 4, 26 NGS studies have identified a greater-than-expected number of genetic variations in the human genome, suggesting that existing monogenic testing systematically miss relevant information. Our analyzes demonstrated that multigenic approach represent a reliable diagnostic tool for HA patients, overcoming for sensitivity and specificity the gene-by-gene strategy. One of the most important aspects of the use of custom gene panels in clinical practice is their ability to be easily upgradable in view of novel discoveries. This aspect is important not only for the chance to extend the diagnostic spectrum, as described in the present study, but also for the possibility to incorporate noncoding regulatory regions that may harbor pathogenic mutations, as described for GATA1 cis elements disrupted in human erythroid disorders. 27, 28 Our paradigmatic cases highlighted how the multi-target sequencing diagnosis may be valuable not only for achieving a correct and definitive diagnosis, but also for guiding treatment. Moreover, it allowed the identification of polygenic conditions, in which the phenotypic variability could be explained by the coinheritance of multiple disease genotypes.
